【BIO-K】 Japan-USA-Asia's Challenges Towards Innovation

May 13[Wed]
10:00 - 12:00
BILINGUAL English/Japanese
Course Leader:
Ken-ichi Arai
Professor Emeritus,
The University of Tokyo/
Director, Chairman,
SBI Biotech Co., Ltd.
Sub-course Leader:
Toichi Takenaka
Chairman, Japan Health Sciences Foundation/
Former Chairman of the Board, Astellas Pharma Inc.

AMED: It's Mission and Perspectives

Makoto Suematsu
President,
Japan Agency for Medical Research and Development (AMED)/
Former Dean, Professor of Biochemistry,
Keio University School of Medicine

[Abstract]
Japan Agency for Medical Research and Development(AMED) aims to accelerate the speech and efficiency of medical R&D for aiding patients over the world. The lecture will show AMED's mission and perspectives of the new Agency.


Microphysiological Systems: Innovative Tools for Drug Development and Disease Modeling


Danilo A. Tagle
Associate Director for Special Initiatives,
National Center for Advancing Translational Sciences,
National Institutes of Health (NIH)

[Abstract]
The goal of the NIH Microphysiological Systems program is to develop bio-engineered microdevices that represent functional units of the 10 major human organ systems: circulatory, respiratory, integumentary, reproductive, endocrine, gastrointestinal, nervous, urinary, musculoskeletal, and immune using hiPSCs. This unique and novel in vitro platform could help ensure that safe and effective therapeutics are identified sooner, and ineffective or toxic ones are rejected early in the drug development process. These microfabricated devices are also useful for modeling human diseases and may prove to be sufficient alternatives to the use of animal models.

[Profile]
Dr. Danilo Tagle is Associate Director for Special Initiatives at the National Center for Advancing Translational Sciences (NCATS). He leads and manages the 1) NIH Microphysiological Systems program, 2) Extracellular RNA Communication program, and 3) the Stimulating Peripheral Activity to Relive Conditions (SPARC) program. These multidisciplinary programs involve coordination of activities with other NIH institutes and centers, including the NIH Common Fund, as well as partnerships with other government agencies, such FDA and DARPA, and the private sector. In addition to being Associate Director for Special Initiatives, Dr. Tagle recently served as Acting Director for the NCATS Office of Grants Management and Scientific Review, and currently serves as Executive Secretary to the NCATS Advisory Council, as well as the Cures as well as the Cures Acceleration Network Review Board.


Driving Economic Growth through the Bio-based Industry:
Opportunities and Challenges for Malaysia


Mohd Nazlee Kamal
Chief Executive Officer,
Malaysian Biotechnology Corp. (BiotechCorp)



[Abstract]
Malaysia’s transformation towards a bio-based economy, for social and national economic growth is fuelled by bio-based innovations. Serving as the key driver in moving the country towards a more resource efficient society, bio-based advancement enhances the economic potential of the country biodiversity and bio-based resources with the objectives of achieving agricultural productivity, making discoveries in healthcare and adopting sustainable industrial processes.
A number of pro bio-based policies have been put in place to address key challenges, improving long term sustainability and fostering effective governance and involvement of stakeholders at all levels; which include the public sector, industry, academia and consumers at large. Effective coordination will further the building of a strong innovation base that will reinforce the local bio-based ecosystem, coupled with coherent and strategic approaches to attract investment, encourage commercialisation, produce skilled workforce and promote bio-entrepreneurship. Addressing the international dimension of the bio-based economy, Malaysia, being the second country in Asia to have a comprehensive bioeconomy strategy is also taking a leading role in promoting international cooperation and collaboration in the development of the bio-based sector.
The end objective would be to position bioeconomy as a significant economic contributor to the national economy, in line with the country’s economic transformation programme.

[Profile]
Dato’ Dr. Mohd Nazlee Kamal is the Chief Executive Officer of the Malaysian Biotechnology Corporation (BiotechCorp), the lead development agency for the biotechnology industry in Malaysia. He is also the Chairman of Malaysian Bio-XCell, a dedicated biotechnology park and ecosystem hub being developed in the southern state of Johor, Malaysia.
With more than 25 years of experience in diverse portfolios in the biotechnology industry, Dato’ Nazlee brings strong acumen in both technical and business aspects of biotechnology to BiotechCorp. Recognised for his industry-wide leadership and vast experience in biotechnology, Dato’ Nazlee played a pivotal role in the formulation of Malaysia’s National Biotechnology Policy and the implementation of the Malaysia’s Bioeconomy Transformation Programme (BTP).
Prior to joining BiotechCorp, he was the CEO of Inno Biologics Sdn Bhd and the Group Managing Director of Inno Bio Ventures Sdn Bhd. The main areas of focus for Inno Bio Group of Companies are biopharmaceutical manufacturing and cell-based diagnostics.
Previous to Inno Bio Group of Companies, Dato’ Nazlee has a wealth of experience encompassing marketing and technical portfolios with multinational companies such as Amersham Biosciences, Sartorius and BBraun. Dato’ Nazlee served 10 years of tenure as a Lecturer at the University of Technology Malaysia (UTM) where he developed the Bioprocess Engineering Program. His innovation, the “External Spinfilter”, is being marketed by Sartorius BBI Systems (Patent No. PI9701436MY-11798-A). Dato’ Nazlee is an active member of the International Society of Pharmaceutical Engineering, Malaysian Biotechnology and Molecular Biology Society, and Institution of Chemical Engineers.
Dato’ Nazlee obtained his PhD. in Chemical Engineering (Bioprocess) from the University of Queensland, Australia and he holds a Master in Application Science Biotechnology from University of New South Wales, Australia.